Adicet Bio, Inc. is a publicly held biotechnology company (Nasdaq: ACET) discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
Location: United States, California, Menlo Park
Employees: 51-200
Total raised: $141M
Investors 6
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| 20.01.2022 | aMoon Fund | amoon.fund... |
| - | OrbiMed | orbimed.co... |
| 11.02.2021 | Abingworth... | abingworth... |
| - | SymBiosis | symbiosis.... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.08.2020 | - | $10M | - |
| 03.10.2019 | Series B | $80M | aMoon Fund |
| 27.01.2016 | Series A | $51M | - |
Mentions in press and media 29
| Date | Title | Description |
| 13.01.2022 | Slone Partners Places Brian Hogan as Chief Financial Officer at InterVenn Biosciences | “Brian Hogan is an extremely smart and innovative financial executive with a track record of success throughout his career in the life sciences,” said Slone Partners President Tara Kochis. SOUTH RIDING, Va. (PRWEB) January 13, 2022 Slone Pa... |
| 06.12.2021 | Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy | Complete and near complete responses observed with ADI-001 starting at lowest dose level in Phase 1 study for the treatment of B-cell Non-Hodgkin’s Lymphoma (ORR=75%, CR=50%) No ADI-001-related serious adverse events, including GvHD, neurot... |
| 29.11.2021 | Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's Lymphoma | ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data Event to be webcast on December 6, 2021 at 8:30 a.m. EST MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio... |
| 18.11.2021 | Adicet Bio : Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors - Form 8-K | Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors Menlo Park, CA and Boston, MA - November 18, 2021 - Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogen... |
| 18.11.2021 | Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors | MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today... |
| 12.11.2021 | Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting - Form 8-K | Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting Adicet's allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intr... |
| 12.11.2021 | Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting | Adicet’s allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the Company’s gamma delta T cell platform Preclini... |
| 11.11.2021 | Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates - Form 8-K | Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates On track to report top-line safety and tolerability data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by year end Announced collaboration wi... |
| 11.11.2021 | Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates | On track to report top-line safety and tolerability data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by year end Announced collaboration with Twist Bioscience to accelerate discovery of gamma delta T cell cancer therapeutics ... |
| 04.11.2021 | Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting | MENLO PARK, Calif. and BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today... |
Show more